The pooled prevalence of cognitive impairment in adults with myelin oligodendrocyte glycoprotein antibody-associated disease: A Systematic Review & Meta-Analysis.
Albert Aboseif, Karlo Toljan, Moritz Niederschweiberer et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed cognitive impairment in adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), using studies with formal neuropsychological testing, and compared prevalence with relapsing-remitting multiple sclerosis (RRMS). Six studies met inclusion criteria. The pooled prevalence of cognitive impairment in MOGAD was 22% (95% CI 13-35%); 51% (95% CI 35% - 67%) had impairment in at least one cognitive domain. Verbal memory and working memory/processing speed were the most frequently affected domains. Cognitive impairment prevalence was 10.5% lower than in RRMS, but the difference was not statistically significant (p = 0.11).
Key findings
- Pooled cognitive impairment prevalence in adults with MOGAD was 22% (95% CI 13-35%).
- Impairment in at least 1 cognitive domain was reported in 51% (95% CI 35% - 67%).
- Verbal memory (19% [CI 10%-34%]) and working memory/processing speed (19% [CI 10%-31%]) were most frequently affected.
- Prevalence was 10.5% lower than in RRMS (32.5% [CI 29-36%], p = 0.11).
Why it matters
The findings indicate that cognitive impairment is a relevant feature to consider when characterizing MOGAD, with memory and processing speed among the domains most often affected. The comparison with RRMS did not establish a statistically significant difference, so the estimates help describe the reported burden rather than demonstrate a distinct cognitive profile.
What to keep in mind
Only 6 studies met inclusion criteria, and the authors call for larger prospective studies to establish prevalence across the age span and clinical spectrum.